Atlas Bio
Runs in silico clinical trials, starting in immunology: a foundation model trained on about 2 million RNA readouts from human tissue predicts each virtual patient's response to several treatments and diseases, to help drug developers choose what to take into Phase II.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-10-27SeedRound
$10M
For: scale its scientific and commercial teams, deepen platform validation and onboard further enterprise clients
HiringModels and platformCommercial roll-out
The company's release, carried in full by Tech.eu and Startupticker; Reuters attributes the figures to the company.
On the deal: Katharina Wilhelm (Partner; joins Atlas Bio's board and spoke for the lead in the announcement, Creandum, joins the board)
- 2026-10-27date disclosed · close date not givenPre-seedRound
$2.5M
Not stated
Disclosed with the seed as a previously unannounced round; the release does not say when it closed.
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.